Clinical Trial Update: Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of dasatinib in patients with advanced ER+/PR+ or HER2+ breast cancer has completed enrollment with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Breast Cancer, Metastasis | Phase 2 | Status: COMPLETED | Results posted: 2010-11-05